Planning ahead
Executive Summary
Bristol told analysts during April 25 conference call that it has scheduled an R&D update for Nov. 7. The company will be through two key events before that date: the disclosure of study results for the antihypertensive Vanlev and the probable onset of generic competition for its largest product, Glucophage (1see related story, p. 16)